Profusa Expands into Precision Diagnostics with $30M PanOmics Platform Acquisition

Got story updates? Submit your updates here. ›

Profusa, a digital health company focused on continuous biochemistry monitoring, announced a strategic expansion into molecular diagnostics through a $30 million Letter of Intent to acquire the PanOmics multi-omics diagnostics platform from BioInsights LLC. The deal will add the PanOmics platform to Profusa's core Lumee real-time biochemistry monitoring technology, positioning the company at the intersection of biosensing, diagnostics, and precision medicine.

Why it matters

The acquisition of the PanOmics platform and Profusa's collaboration with the Mayo Clinic will help the company build a differentiated, scalable presence in precision diagnostics and surgical monitoring. This will be instrumental in establishing a platform capable of supporting multiple indications and long-term growth, particularly in the high-growth pancreatic cancer market.

The details

Under the terms of the Letter of Intent, Profusa will acquire exclusive rights to the PanOmics platform and related know-how for approximately $30 million in equity securities. BioInsights will provide access to clinical samples for validation and receive a 3% royalty on net revenue. The proposed transaction remains subject to due diligence, shareholder approval, and closing conditions. The integration of PanOmics with Profusa's biosensing technologies is expected to enable a capital-efficient and accelerated path from development to revenue generation through multi-indication diagnostic assays, real-time physiological monitoring solutions, and data-driven clinical decision tools.

• Profusa announced the Letter of Intent on April 6, 2026.

What they’re saying

What’s next

The proposed transaction remains subject to completion of due diligence, shareholder approval, and customary closing conditions.